This setback for the group follows the rejection by the US in October of its anti-coagulant pill Exanta.

"I am determined to improve our development and regulatory performance, restore confidence in the company and value to shareholders," said chief executive Tom McKillop.

Shares in Anglo-Swedish drug have closed down 8% in UK trade after the failure of its Iressa drug in a major clinical trial.

"This would be two of the three blockbuster drugs that were meant to power the company forward failing... and we've got risks on Crestor," said Nick Turner, analyst at brokers Jefferies.

The company said Mr Patterson would make "substantial changes to the clinical organisation and its processes".

